Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.

Arvidson, Nils Gunnar; Guðbjörnsson, Björn; Elfman, Lena; Rydén, Ann Christin; Tötterman, Thomas H.; Hällgren, Roger

doi:10.1136/ard.53.8.521

Cited by 192 publications

(131 citation statements)

References 22 publications

(1 reference statement)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…IL-6 mRNA levels in the patients' PBMC decreased to values below the 95% confidence interval of the normal controls. By contrast, physiological variations in IL-6 mRNA levels related to diurnal fluctuations [25] in three normal individuals remained within the 95% confidence interval of the controls.…”

Section: In Vivo Administration Of Anti-icam-1 Moab Induces a Temporamentioning

confidence: 93%

Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)

Schulze‐Koops

Lipsky

Kavanaugh

et al. 1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

There is persistent excessive production of a number of pro‐inflammatory cytokines in patients with rheumatoid arthritis (RA). A number of experimental therapies have been found to be effective in the treatment of RA, although the effects of these therapies on cytokine production have not been evaluated. One such experimental therapy involves administration of a MoAb to intercellular adhesion molecule‐1 (ICAM‐1) that has been shown to be clinically beneficial in approximately 60% of the patients, with some patients responding for up to 11 months. The current studies were carried out to determine whether the success of this therapy was associated with changes in mRNA levels for pro‐inflammatory and other monocyte‐derived cytokines in peripheral blood mononuclear cells (PBMC). Cytokine mRNA levels were assessed in freshly isolated unstimulated PBMC by semiquantitative reverse transcription‐polymerase chain reaction (RT‐PCR) after minimal in vitro manipulation of the cells. Anti‐ICAM‐1 MoAb administration was followed by an increase in IL‐1β, IL‐8, and tumour‐necrosis factor‐alpha (TNF‐α) mRNA detected at 2 or 24 h after the initial infusion in the clinical responders, but no persistent change in these cytokine mRNA levels were observed that correlated with clinical benefit. By contrast, IL‐6 mRNA levels declined immediately after the first MoAb infusion and reached pretreatment values variably after the 5 day treatment course. IL‐6 mRNA levels remained significantly reduced in patients responding to therapy 1 month after treatment. Fluctuations in monocyte numbers within the PBMC after treatment did not account for the observed changes in cytokine mRNA levels. The results suggest that a decline in IL‐6 mRNA levels is a pharmacological action of the MoAb to ICAM‐1. Moreover, persistently diminished IL‐6 mRNA levels induced by anti‐ICAM‐1 MoAb might be associated with the long‐term benefit of this therapy. In addition, monitoring the activation status of monocytes in circulating PBMC may be useful in predicting response to therapy and warrants further investigation in a larger study population.

show abstract

Section: In Vivo Administration Of Anti-icam-1 Moab Induces a Temporamentioning

confidence: 93%

Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)

Schulze‐Koops

Lipsky

Kavanaugh

et al. 1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…has an important role in inflammation and tissue destruction in joint diseases such as RA (17), and its concentration is elevated in the synovial fluids of arthritic patients (18,19). …”

Section: Discussionmentioning

confidence: 99%

<b>Pro-inflammatory Cytokine Production in Co-culture of Human Monocytes and Synovial Fibroblasts from the Human Temporomandibular Joint </b>

et al. 2017

View full text Add to dashboard Cite

The synovial membrane is composed of fibroblast-like cells (synovial fibroblasts) and macrophage-like cells. Synovial fibroblasts and monocytes/macrophages are believed to interact and to play a critical role in the development of synovial inflammation. In this study, we investigated the protein production of pro-inflammatory cytokines in co-culture of synovial fibroblasts isolated from the temporomandibular joint (TMJ) and monocytes isolated from peripheral blood. Monocytes that had attached to the plastic surface after culture for 3 days in RPMI containing 10% FBS, exhibited two types of morphologies:ʠfried eggʡandʠspindle-likeʡ . Both types of monocytes stained positive for the macrophagespecific markers CD14 and CD68. Synovial fibroblasts were co-cultured with these monocytes for 12 days. Synovial fibroblasts or monocytes were also cultured alone for 12 days. The conditioned media were collected every 3 days, following which fresh medium was added to each culture. The protein concentrations of IL-1 , IL-6, and IL-8 in the conditioned media were measured using ELISA. The protein production of IL-1 , IL-6 and IL-8 was greatly increased in the co-culture of synovial fibroblasts and monocytes compared to each monoculture. These data suggest that interaction between monocytes/ macrophages and synovial fibroblasts is likely to contribute to the promotion of, and to increase the inflammatory condition in the TMJ.

show abstract

“…For instance, there is a circadian rhythm in the plasma concentration of C -reactive protein [26] and interleukin-6 [27] of patients with rheumatoid arthritis. Patients with osteoarthritis tend to have less pain in the morning and more at night; while those with rheumatoid arthritis, have pain that usually peaks in the morning and decreases throughout the day.…”

Section: Arthritismentioning

confidence: 99%

Recent trends in pulsatile drug delivery systems - A review.

Sharma¹,

Srikanth²,

Uhumwangho³

et al. 2010

Int j Drug delivery

View full text Add to dashboard Cite

The purpose of writing this review on pulsatile drug delivery systems (PDDS) is to compile the recent literatures with special focus on the different types and approaches involved in the development of the formulation. PDDS are gaining importance in the field of pharmaceutical technology as these systems deliver the right dose at specific time at a specific site. Some of the disease conditions wherein PDDS are promising include duodenal ulcer, cardiovascular diseases, arthritis, asthma, diabetes, neurological disorder, cancer, hypertension and hypercholesterolemia. PDDS can be classified into time controlled systems wherein the drug release is controlled primarily by the delivery system, stimuli induced PDDS in which release is controlled by the stimuli, such as the pH or enzymes present in the intestinal tract or enzymes present in the drug delivery system and externally regulated system where release is programmed by external stimuli like magnetism, ultrasound, electrical effect and irradiation. This review also summarizes some current PDDS already available in the market. These systems are useful to several problems encountered during the development of a pharmaceutical dosage form.

show abstract

Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.

Abstract: Objectives-To test the hypothesis of a diurnal variation in circulating levels of interleukin-6 (IL-6) and/or tumour necrosis factor-alpha (TNF-alpha) in rheumatoid arthritis and other inflammatory connective tissue diseases.

Cited by 192 publications

References 22 publications

Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)

Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)

<b>Pro-inflammatory Cytokine Production in Co-culture of Human Monocytes and Synovial Fibroblasts from the Human Temporomandibular Joint </b>

Recent trends in pulsatile drug delivery systems - A review.

Contact Info

Product

Resources

About